However, some cancer cells are intrinsically resistant and also the drug-exposed cancer cells often get a resistance. Discovery and exploitation of structurally different new categories of antimicrotubule agents may triumph over such problem. For example, the clinical utility with structurally different MT stabilizers to help overcome the Taxol-resistance has been reported. The complementary approaches may
(Read More…)




